Karin Walker
Direttore/Membro del Consiglio presso CYCLACEL PHARMACEUTICALS, INC.
Patrimonio netto: 6 696 $ in data 30/04/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Paul McBarron | M | 63 | 22 anni | |
| Christopher Henney | M | 83 | 18 anni | |
| Brian Schwartz | M | 52 | 4 anni | |
| Gene Kinney | M | 55 | 12 anni | |
| Daniel Welch | M | 66 | - | |
| Spiro Rombotis | M | 65 | 27 anni | |
| Lars Ekman | M | 74 | 12 anni | |
| Tran Nguyen | M | 50 | 11 anni | |
| Richard Collier | M | 70 | 12 anni | |
| Samuel Barker | M | 81 | 10 anni | |
| Michael J. Malecek | M | 58 | 5 anni | |
| Randy Fawcett | M | - | - | |
| Paula Cobb | F | 51 | 5 anni | |
| Wagner M. Zago | M | 51 | 12 anni | |
| Brandon Smith | M | 50 | 4 anni | |
| Oleg Nodelman | M | 47 | 5 anni | |
| Robert Spiegel | M | 73 | 6 anni | |
| Shane Cooke | M | 61 | 12 anni | |
| Dennis Selkoe | M | 80 | 11 anni | |
| Kenneth Ferguson | M | 68 | 2 anni | |
| Yvonne M. Tchrakian | F | - | 10 anni | |
| Hideki Garren | M | 60 | 3 anni | |
| Carol Karp | F | 71 | 8 anni | |
| Helen Kim | F | 61 | 2 anni | |
| Michael Bachner | M | - | 2 anni | |
| William Dunn | M | - | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Jonas Grossman | M | 50 | 2 anni | |
| Arthur Levinson | M | 73 | 4 anni | |
| Dale B. Schenk | M | 66 | 4 anni | |
| Nicholas Khadder | M | 50 | 6 anni | |
| Andrew McDonald | M | 50 | 1 anni | |
| Patrick Pichette | M | 61 | 3 anni | |
| Barry Dennis | M | 59 | - | |
| John Steven Ziegler | M | 65 | - | |
| David Dobkin | M | 45 | 1 anni | |
| Jennifer Zibuda | F | - | 3 anni | |
| Sanjiv Patel | M | 50 | 2 anni | |
| Michael Rice | M | 59 | 1 anni | |
| Gary Loeb | M | 54 | 2 anni | |
| Christopher Chai | M | 58 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 anni |
| Karl Härfstrand | M | 66 | 9 anni | |
| Arthur William Homan | M | 64 | 5 anni | |
| Judy Chiao | M | 64 | 17 anni | |
| Tara Nickerson | M | 51 | 6 anni | |
| Carole Piwnica | F | 66 | 12 anni | |
| Peter G. Milner | M | 68 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 17 anni |
| Caryn McDowell | F | 54 | 1 anni | |
| Joel Velasco | M | - | - | |
| Krishna R. Polu | M | 50 | 4 anni | |
| Sarah Noonberg | M | 56 | 1 anni | |
| Cynthia Smith | F | 55 | 5 anni | |
| Barbara McNeil | M | 83 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 14 anni |
| Geoff Duyk | M | 64 | 5 anni | |
| Radhika Tripuraneni | M | 44 | 4 anni | |
| David B. Mcninch | M | 55 | - | |
| James Young Richardson | M | 57 | - | |
| Matthew Panuwat | M | 47 | 1 anni | |
| Jason Raleigh | M | 47 | 5 anni | |
| Amartya Basu | M | - | 3 anni | |
| Courtney Phillips | F | 49 | 2 anni | |
| Peter M. Strumph | M | 59 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 anni |
| Louis Yu | M | 73 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 anni |
| Martin Koller | M | 73 | 4 anni | |
| Peter P. Boynton | M | 69 | - | |
| Paul J. Frohna | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 2 anni |
| Mario Neutel Soares Portela | M | 62 | 3 anni | |
| Anne-Marie S. Duliege | M | 64 | 9 anni | |
| Anne Champsaur | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 anni |
| Joseph M. Davie | M | 84 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 anni |
| Douglas T. Sheehy | M | 57 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 5 anni |
| Robert F. Venteicher | M | 78 | 6 anni | |
| Jennifer Hodge | F | 55 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 7 anni |
| Bruce Philip Pritchard | M | 51 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 2 anni |
| Michael T. Sweeney | M | 63 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 anni |
| Rebecca Lucia | F | 52 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 anni |
| Philip Wells | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 anni |
| David Banks | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 4 anni |
| Jeffrey H. Knapp | M | 58 | 7 anni | |
| Hsiao Lieu | M | 53 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 3 anni |
| Peter Hutt | M | 89 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 8 anni |
| Huang I-Zu | M | - |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 6 anni |
| Shay Weisbrich | F | 71 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 1 anni |
| David C. McCaleb | M | 70 |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | 10 anni |
| Mark Kirschbaum | M | 63 | 4 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 54 | 64.29% |
| Irlanda | 31 | 36.90% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Karin Walker
- Contatti personali
